Nasdaq:CLRBZ

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrm Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

June 01, 2026 08:05 ET  | Source: Cellectar Biosciences, Inc. Approximately 80% Major Response Rate and Duration of Response Exceeding…

5 days ago

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors December 16, 2025 08:05 ET  | Source:…

6 months ago